Notably, in a large meta-analysis of 43 observational studies including stage IIIB-IV NSCLC patients treated with either chemotherapy combined with or without bevacizumab and EGFR TKIs, Goulding et al found that KRAS mutations are associated with a significant shorter overall survival (HR=1.71; 95%CI [1.07-2.84]) and progression-free survival (HR=1.18; 95%CI [1.02-1.36]) (61). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.